LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
LakeShore Biopharma (Nasdaq: LSB) has provided financial guidance for the first half of fiscal year 2025 and reaffirmed its full-year guidance, highlighting strong execution and positive business momentum. The company anticipates double-digit year-over-year revenue growth for FY2025 and expects to achieve breakeven during this period. Preliminary total revenue for the first six months is estimated between RMB350 million to RMB380 million, representing a 28% to 39% growth from the same period in FY2024.
LakeShore Biopharma is pursuing strategic initiatives including cost reductions, organizational restructuring, and management process enhancements to boost operational efficiency. The company is also focused on driving future growth through strategic alliances, product licensing, asset purchases, partnerships, and co-promotion deals. CEO Xu Wang expressed confidence in maintaining positive momentum and achieving financial and operational objectives, noting the company's second position in China's Rabies vaccine market and its commitment to enhancing sustainability, efficiency, and innovation.
LakeShore Biopharma (Nasdaq: LSB) ha fornito indicazioni finanziarie per il primo semestre dell'anno fiscale 2025 e ha confermato le previsioni per l'intero anno, evidenziando una forte esecuzione e un positivo slancio aziendale. L'azienda prevede una crescita dei ricavi a due cifre rispetto all'anno precedente per l'anno fiscale 2025 e si aspetta di raggiungere il pareggio durante questo periodo. Il fatturato totale preliminare per i primi sei mesi è stimato tra RMB350 milioni e RMB380 milioni, rappresentando una crescita del 28% al 39% rispetto allo stesso periodo dell'anno fiscale 2024.
LakeShore Biopharma sta perseguendo iniziative strategiche tra cui riduzioni dei costi, ristrutturazione organizzativa e miglioramenti nei processi di gestione per aumentare l'efficienza operativa. L'azienda è inoltre focalizzata sul guidare la crescita futura attraverso alleanze strategiche, licenze di prodotto, acquisto di asset, partnership e accordi di co-promozione. Il CEO Xu Wang ha espresso fiducia nel mantenere un andamento positivo e nel raggiungere obiettivi finanziari e operativi, sottolineando la seconda posizione dell'azienda nel mercato dei vaccini contro la rabbia in Cina e il suo impegno per migliorare sostenibilità, efficienza e innovazione.
LakeShore Biopharma (Nasdaq: LSB) ha proporcionado orientación financiera para la primera mitad del año fiscal 2025 y ha reafirmado su pronóstico para todo el año, destacando una fuerte ejecución y un positivo impulso comercial. La compañía anticipa un crecimiento de ingresos de dos dígitos en comparación con el año anterior para el año fiscal 2025 y espera alcanzar el equilibrio durante este período. Se estima que los ingresos totales preliminares para los primeros seis meses oscilarán entre RMB350 millones y RMB380 millones, lo que representa un crecimiento del 28% al 39% en comparación con el mismo período del año fiscal 2024.
LakeShore Biopharma está llevando a cabo iniciativas estratégicas que incluyen reducciones de costos, reestructuración organizativa y mejoras en los procesos de gestión para aumentar la eficiencia operativa. La empresa también se enfoca en impulsar el crecimiento futuro a través de alianzas estratégicas, licencias de productos, adquisiciones de activos, asociaciones y acuerdos de co-promoción. El CEO Xu Wang expresó confianza en mantener un impulso positivo y alcanzar objetivos financieros y operativos, señalando la segunda posición de la empresa en el mercado de vacunas contra la rabia en China y su compromiso con la sostenibilidad, eficiencia e innovación.
레이크쇼어 바이오파마 (Nasdaq: LSB)는 2025 회계연도 상반기 재무 전망을 제공하고 연간 가이던스를 재확인하며 강력한 실행력과 긍정적인 사업 모멘텀을 강조했습니다. 이 회사는 2025 회계연도에 대해 전년 대비 두 자릿수 수익 성장을 예상하고 있으며, 이 기간 동안 손익 분기점에 도달할 것으로 기대하고 있습니다. 상반기 총 수익은 RMB3억 5천만에서 RMB3억 8천만 사이로 추정되며, 2024 회계연도 같은 기간에 비해 28%에서 39% 성장하는 것으로 나타났습니다.
레이크쇼어 바이오파마는 비용 절감, 조직 재편성 및 관리 프로세스 개선을 포함한 전략적 이니셔티브를 추진하여 운영 효율성을 높이고 있습니다. 이 회사는 또한 전략적 제휴, 제품 라이센스, 자산 구매, 파트너십 및 공동 마케팅 계약을 통해 미래 성장을 지속적으로 촉진하는 데 주력하고 있습니다. CEO 쉬 왕은 긍정적인 모멘텀을 유지하고 재무 및 운영 목표를 달성할 자신이 있다고 표현하며, 회사의 중국 광견병 백신 시장에서의 두 번째 위치와 지속 가능성, 효율성 및 혁신 향상에 대한 회사의 헌신을 강조했습니다.
LakeShore Biopharma (Nasdaq: LSB) a fourni des prévisions financières pour la première moitié de l'exercice 2025 et a réaffirmé ses prévisions pour l'année entière, mettant en lumière une exécution solide et un élan commercial positif. L'entreprise prévoit une croissance des revenus à deux chiffres par rapport à l'année précédente pour l'exercice 2025 et s'attend à atteindre l'équilibre durant cette période. Le chiffre d'affaires total préliminaire pour les six premiers mois est estimé entre RMB350 millions et RMB380 millions, représentant une croissance de 28% à 39% par rapport à la même période de l'exercice 2024.
LakeShore Biopharma poursuit des initiatives stratégiques, y compris réductions de coûts, réorganisation organisationnelle et amélioration des processus de gestion afin d'accroître l'efficacité opérationnelle. L'entreprise est également axée sur la stimulation de la croissance future grâce à des alliances stratégiques, des licences de produits, l'achat d'actifs, des partenariats et des accords de co-promotion. Le PDG Xu Wang a exprimé sa confiance dans le maintien d'un élan positif et l'atteinte des objectifs financiers et opérationnels, notant la deuxième position de l'entreprise sur le marché des vaccins contre la rage en Chine et son engagement à améliorer la durabilité, l'efficacité et l'innovation.
LakeShore Biopharma (Nasdaq: LSB) hat eine finanzielle Prognose für die erste Hälfte des Geschäftsjahres 2025 vorgelegt und seine Jahresprognose bekräftigt, wobei die starke Ausführung und die positive Geschäftsdynamik hervorgehoben wurden. Das Unternehmen erwartet doppelt so hohe Umsatzzuwächse im Vergleich zum Vorjahr für das Geschäftsjahr 2025 und plant, in diesem Zeitraum die Gewinnschwelle zu erreichen. Der vorläufige Gesamtumsatz für die ersten sechs Monate wird auf RMB350 Millionen bis RMB380 Millionen geschätzt, was ein Wachstum von 28% bis 39% im Vergleich zum gleichen Zeitraum im Geschäftsjahr 2024 darstellt.
LakeShore Biopharma verfolgt strategische Initiativen, darunter Kostensenkungen, organisatorische Umstrukturierungen und Verbesserung der Managementprozesse, um die Betriebseffizienz zu steigern. Das Unternehmen konzentriert sich auch darauf, künftiges Wachstum durch strategische Allianzen, Produktlizenzen, Asset-Käufe, Partnerschaften und Co-Promotions voranzutreiben. CEO Xu Wang äußerte sich zuversichtlich, dass das positive Momentum aufrechterhalten wird und die finanziellen sowie betrieblichen Ziele erreicht werden, wobei die zweite Position des Unternehmens im chinesischen Tollwutimpfstoffmarkt und das Engagement für Nachhaltigkeit, Effizienz und Innovation hervorgehoben wurden.
- Anticipated double-digit year-over-year revenue growth for FY2025
- Estimated 28% to 39% revenue growth for the first six months of FY2025
- Expected to achieve breakeven during FY2025
- Secured second position in China's Rabies vaccine market
- Pursuing strategic initiatives to boost operational efficiency and reduce costs
- Driving future growth through strategic alliances and partnerships
- None.
Insights
LakeShore Biopharma's financial guidance for FY2025 indicates strong momentum and execution. The company projects double-digit year-over-year revenue growth and expects to reach breakeven during the period. Preliminary revenue estimates for H1 FY2025 are between
The company's strategic initiatives, including cost reductions and organizational restructuring, aim to boost operational efficiency. This focus on streamlining operations, combined with efforts to drive growth through strategic alliances, positions LakeShore Biopharma well for future profitability. The company's second position in China's Rabies vaccine market further solidifies its market presence.
For investors, this guidance suggests a positive outlook, with the company on track to improve its financial performance. The expected breakeven point in FY2025 is particularly noteworthy, as it indicates a potential turning point towards profitability. However, investors should monitor the execution of these strategies and the impact of any new partnerships on long-term growth prospects.
LakeShore Biopharma's previously issued guidance anticipated double-digit year-over-year revenue growth during Fiscal Year 2025 and noted that the Company expected to achieve breakeven during the period. The Company's performance in the first six months of its Fiscal Year 2025 has demonstrated solid progress towards these goals, with a preliminary total revenue estimate for the first six months in the range of
In addition to advancing its existing pipeline, LakeShore Biopharma has been vigorously pursuing strategic initiatives including cost reductions, organizational restructuring and optimization, and management process enhancements to boost operational efficiency and eliminate non-essential expenditures. Furthermore, the Company is also committed to driving future growth through strategic alliances, including product licensing, asset purchase agreements, partnerships, and co-promotion deals with more diversified pipeline products.
Mr. Xu Wang, Chief Executive Officer of the Company, commented, "By reaffirming our full-year guidance, we are expressing belief in our ability to maintain our positive momentum and achieve our financial and operational objectives. With our new management team in place, Lakeshore Biopharma has not only maintained smooth operations, but also secured second position in
About LakeShore Biopharma
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of LakeShore Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, LakeShore Biopharma's ability to source and retain talent, and the cash position of LakeShore Biopharma. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "potential," "forecast," "intend," "will," "expect," "anticipate," "believe," "goal," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma's management and are not predictions of actual performance.
LakeShore Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission (the "SEC"), and other risks described in documents subsequently filed or furnished by the Company from time to time with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update these forward-looking statements.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com
View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-provides-fiscal-half-year-2025-financial-guidance-and-reaffirms-fiscal-year-2025-financial-guidance-302270029.html
SOURCE LakeShore Biopharma Co., Ltd.
FAQ
What is LakeShore Biopharma's revenue guidance for the first half of fiscal year 2025?
Has LakeShore Biopharma (LSB) reaffirmed its full-year guidance for fiscal year 2025?
What strategic initiatives is LakeShore Biopharma (LSB) pursuing to boost operational efficiency?
What is LakeShore Biopharma's (LSB) position in China's Rabies vaccine market as of October 2024?
